Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

MAB858-2

Sigma-Aldrich

Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G

clone 131-2G, from mouse

Sinonimo/i:

RSV

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

Forma dell’anticorpo

purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

131-2G, monoclonal

Reattività contro le specie

human

Produttore/marchio commerciale

Chemicon®

tecniche

ELISA: suitable
immunofluorescence: suitable

Isotipo

IgG1κ

Condizioni di spedizione

wet ice

Descrizione generale

RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.

Specificità

Glycoprotein, 89 kD. Recognizes both A and B strains.

Immunogeno

A2
Epitope: some type B strains

Applicazioni

Detect Respiratory Syncytial Virus using this Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G validated for use in ELISA & IF.
ELISA

Indirect Immunofluorescence (fresh frozen tissue sections)

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Stato fisico

Format: Purified
Purified immunoglobulin. 1 mg/mL in 0.02M PB with 0.25M NaCl, pH=7.6 containing 0.1% sodium azide.

Stoccaggio e stabilità

Maintain at 2 to 8° C in aliquots for up to 12 months after date of receipt. Do not store in diluted format.

Altre note

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Note legali

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Myra N Widjojoatmodjo et al.
Virology journal, 7, 114-114 (2010-06-08)
Respiratory syncytial virus (RSV) is a primary cause of serious lower respiratory tract illness for which there is still no safe and effective vaccine available. Using reverse genetics, recombinant (r)RSV and an rRSV lacking the G gene (DeltaG) were constructed
Exploratory Spatial Analysis of in vitro Respiratory Syncytial Virus Co-infections.
Simeonov, I; Gong, X; Kim, O; Poss, M; Chiaromonte, F; Fricks, J
Viruses null
Bo Liang et al.
Journal of virology, 93(7) (2019-01-18)
Human respiratory syncytial virus (RSV) is a major pediatric respiratory pathogen. The attachment (G) and fusion (F) glycoproteins are major neutralization and protective antigens. RSV G is expressed as membrane-anchored (mG) and -secreted (sG) forms, both containing a central fractalkine-like
Caixia Su et al.
NPJ vaccines, 7(1), 168-168 (2022-12-20)
Respiratory syncytial virus (RSV) infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection. Previously we demonstrated that an RSV vaccine, BARS13, consisting
Ana M Nuñez Castrejon et al.
Journal of virology, 96(7), e0220121-e0220121 (2022-03-11)
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.